Approval Is Not Access: Why Canadian Patients Still Wait for Medicines After Regulatory Success

Canada has one of the world's most rigorous regulatory systems for medicines. Yet approval alone does not guarantee that patients will receive timely access to treatment. Across the country, medicines that have demonstrated safety and efficacy can still face prolonged delays before reaching patients through public reimbursement systems. The challenge is no longer simply scientific approval. Increasingly, it is a systems problem.

The Canadian medicines access pathway illustrates this complexity. A therapy may receive authorization from Health Canada, but that approval represents only one stage in a much larger process involving health technology assessment (HTA), pricing negotiations, provincial formulary decisions, reimbursement criteria, operational implementation, and real-world delivery. Each stage introduces additional timelines, stakeholders, and decision-making frameworks. As a result, patients may wait months or even years between regulatory approval and meaningful access to treatment (Salek et al., 2019).

This gap between approval and access reflects a broader structural issue within healthcare systems. Clinical evidence is often generated and evaluated in isolation from the operational realities that ultimately determine whether therapies reach patients. Regulatory agencies assess safety and efficacy. HTA bodies evaluate clinical and economic value. Provincial systems assess affordability and budget impact. Healthcare providers focus on delivery logistics and patient management. Patients themselves experience the consequences of fragmentation across all these systems simultaneously. Yet these groups frequently operate within separate silos, with limited coordination across the full access pathway.

The growing discussion around managed access agreements (MAAs) highlights this tension. MAAs are intended to address uncertainty by enabling conditional or staged reimbursement while additional evidence is collected in real-world settings. In theory, they create a bridge between evidence generation and patient access. However, the Canadian context reveals substantial implementation challenges. Questions remain around governance structures, data collection capacity, interoperability, funding responsibilities, transparency, and the operational burden placed on healthcare systems. Without integrated infrastructure, MAAs risk becoming administratively complex rather than functionally transformative (McPhail & Bubela, 2023).

Importantly, these challenges are not solely policy problems. They are implementation problems. Delays in medicines access rarely emerge from a single point of failure. Instead, they occur when evidence generation, reimbursement strategy, regulatory planning, data systems, provider workflows, and patient realities are not aligned early enough in the process. A medicine may succeed scientifically while failing operationally. Similarly, a reimbursement strategy may appear effective on paper but become difficult to execute within fragmented healthcare environments.

This is particularly important as healthcare systems move toward more personalized therapies, rare disease treatments, and high-cost biologics. These therapies often carry greater evidentiary uncertainty, more complex reimbursement negotiations, and significant operational demands for monitoring and delivery. As the Canadian system evolves, success will increasingly depend not only on clinical innovation, but also on the ability to coordinate systems around implementation.

The future of medicines access in Canada will likely require greater integration across the full healthcare ecosystem. Regulatory science, HTA, reimbursement strategy, health informatics, and real-world evidence generation can no longer function as parallel processes with limited interaction. Instead, they must operate as interconnected components of a broader access strategy. Real-world data systems, interoperability infrastructure, and patient-centered implementation planning will become increasingly important in reducing delays and improving equitable access.

Ultimately, approval is not access. Regulatory success is only meaningful if patients can realistically obtain, continue, and benefit from treatment in practice. The next challenge for healthcare systems is not simply developing innovative medicines, but building systems capable of translating innovation into consistent, timely, and equitable patient access.